Formulations of glucagon-like-peptide-2 (glp-2) analogues
AssigneeZealand Pharma A/S
InventorsHenrik Rajesh Kumar PARSHAD, Lise GIEHM, Claes MELANDER
Life of this patent
Estimating the term…
Loading patent…
AssigneeZealand Pharma A/S
InventorsHenrik Rajesh Kumar PARSHAD, Lise GIEHM, Claes MELANDER
Estimating the term…
Liquid formulations of GLP-2 analogues are described that make it possible to include a preservative while allowing the formulation to be stabilised for long term storage as liquids and/or as multi-dose liquid formulations. The development of these formulations is base on the finding that that reducing the pH of the formulation to below 7.0, e.g. to a pH between about pH 5.0 and about 6.8, was able to offset the effect that the addition of a preservative such as meta-cresol has on the physical stability of the formulation. Additionally, the addition of an excipient such as propylene glycol was shown to be able to offset the effect that the addition of a preservative, such as meta-cresol, has on the physical stability of the formulation. This opens up the possibility of being able to deliver the GLP-2 analogues as multi-dose formulations, for example allowing the use of the formulations in a drug delivery device.
A stable liquid pharmaceutical multi-dose formulation, the formulation comprising a glucagon-like peptide 2 (GLP-2) analogue, wherein the GLP-2 analogue is represented by the formula:
A stable liquid pharmaceutical multi-dose formulation, the formulation comprising a glucagon-like peptide 2 (GLP-2) analogue, wherein the GLP-2 analogue is represented by the formula:
The formulation according to any one of the preceding claims, wherein the GLP-2 analogue is present in the formulation at a concentration of about 1 mg/mL to about 20 mg/mL.
The formulation according to any one of the preceding claims, wherein the GLP-2 analogue is present in the formulation at a concentration of about 2 mg/mL to about 15 mg/mL.
The formulation according to any one of the preceding claims, wherein the formulation is a ready-to-use formulation.
The formulation according to any one of the preceding claims, wherein the GLP-2 analogue is present in the formulation at a concentration of about 2 mg/mL, 10 mg/mL or 20 mg/mL.
The formulation according to any one of the preceding claims, wherein the histidine buffer is present in the formulation at a concentration of about 5 mM to about 25 mM.
The formulation according to any one of the preceding claims, wherein the mannitol is present in the formulation at a concentration of about 150 mM to about 250 mM.
The formulation according to any one of the preceding claims, wherein the histidine buffer is L-histidine.
The formulation according to any one of the preceding claims, wherein the mannitol is D-mannitol.
The formulation according to any one of the preceding claims, wherein the formulation is stable at 2-8° C. for at least 6 months, at least 12 months, at least 18 months or at least 24 months.
The formulation according to any one of the preceding claims which is sterile.
The formulation according to any one of the preceding claims, wherein the formulation is administration to a subject by injection.
The formulation according to any one of the preceding claims, wherein the GLP-2 analogue is provided as an acetate salt.
The formulation according to any one of the preceding claims, wherein the GLP-2 analogue is ZP1848 or ZP1848-acetate.
Use of a formulation comprising a glucagon-like peptide 2 (GLP-2) analogue, wherein the GLP-2 analogue is represented by the formula:
Use of a formulation comprising a glucagon-like peptide 2 (GLP-2) analogue, wherein the GLP-2 analogue is represented by the formula:
A process for producing a stable liquid pharmaceutical formulation comprising a glucagon-like peptide 2 (GLP-2) analogue, wherein the GLP-2 analogue is represented by the formula:
A process for producing a stable liquid pharmaceutical formulation comprising a glucagon-like peptide 2 (GLP-2) analogue, wherein the GLP-2 analogue is represented by the formula:
Dependencies are inferred from the claim text.